OSCR
Oscar Health, Inc.
OSCR has the edge over SEPN overall, supported by stronger fundamentals and stronger modeled upside.
SEPN
Septerna, Inc.
SEPN has lower modeled downside risk, despite its lower overall score.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
SEPN Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
SEPN's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
SEPN PE Valuation
SEPN has no meaningful PE right now: it lost money over the past year.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over SEPN on the outlook, with more favorable earnings expectations.
SEPN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect SEPN's losses to grow, with revenue growing. However, they disagree widely on these estimates.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over SEPN in the latest year-over-year earnings comparison.
SEPN Earnings Per Share
SEPN has swung to a loss: it lost $1.28 per share over the past year, after a profit the year before.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR's revenue has grown year over year every quarter since early 2021: $5.1B last quarter, up 72% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over SEPN on profitability, with a higher operating margin.
SEPN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $18.9M | -12% |
| Q2 2026 | $26.7M | +22376% |
| Q1 2026 | $26.5M | +12011% |
| Q4 2025 | $24.1M | +11276% |
| Q3 2025 | $21.5M | +12113% |
| Q2 2025 | $119K | -68% |
| Q1 2025 | $219K | -31% |
| Q4 2024 | $212K | +80% |
SEPN's revenue is growing: $19M last quarter, down 12% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -144% | -156 points |
| Q2 2026 | -63% | +24288 points |
| Q1 2026 | -50% | +11781 points |
| Q4 2025 | -66% | +11593 points |
| Q3 2025 | 12% | +12825 points |
| Q2 2025 | -24351% | -19469 points |
| Q1 2025 | -11831% | -6945 points |
| Q4 2024 | -11659% | -40742 points |
SEPN's operating margin was −144% last quarter, down 156 points from the same quarter a year ago.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over SEPN on cash generation, producing positive trailing cash flow while its opponent burns cash.
SEPN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$13.9M | -108% |
| Q2 2026 | -$22.2M | -$1.8M |
| Q1 2026 | -$26.5M | -$2.7M |
| Q4 2025 | -$15.1M | +$6.5M |
| Q2 2025 | -$20.3M | -$7.2M |
| Q1 2025 | -$23.7M | -$6.3M |
| Q4 2024 | -$21.6M | -$11.5M |
SEPN has burned cash in almost every quarter: −$78M over the past year, against $103M the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
SEPN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +4.2% | +1.9M shares |
| 1 year | +2.9% | +1.3M shares |
SEPN has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2024 | — |
| Q1 2024 | $1,000 |
| Q4 2023 | — |
| Q3 2023 | $1,000 |
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
SEPN Net Leverage
SEPN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
SEPN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 57.3 | Neutral |
| Stochastic | 62.7 | Neutral |
SEPN's weekly RSI is 57 (neutral) and its Stochastic is 63 (neutral).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
SEPN PE vs Healthcare Sector
SEPN has no meaningful PE right now: it lost money over the past year.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
SEPN has stronger trend alignment. OSCR is above 5 of 5 weekly averages versus SEPN above 4 of 4.
SEPN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $40.7 | 3% above |
| 20 week MA | $38.6 | 8.4% above |
| 50 week MA | $31.9 | 31% above |
| 100 week MA | $22.9 | 83% above |
SEPN is in an uptrend: it's above all four of its weekly moving averages, and 83% above its 100-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over SEPN on returns for 2026, with the stronger performance.
SEPN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2024 | $21.4 | $25.3 | +18% |
| 2025 | $25.3 | $28.6 | +13% |
| 2026 YTD | $28.6 | $41.9 | +46% |
SEPN has finished every year since 2024 higher, and it's up 46% so far in 2026.